Bayer, Orion win FDA priority review for darolutamide in prostate cancer

1st May 2019 Uncategorised 0

Darolutamide is an investigational, non-steroidal androgen receptor antagonist.

More: Bayer, Orion win FDA priority review for darolutamide in prostate cancer
Source: News